News

Laurent Pharmaceuticals Presents Results from Phase 2 Clinical Study of LAU-7b in Cystic Fibrosis at the NACFC 2022

3 November 2022

LAU-7b first inflammation-controlling drug to demonstrate clinical benefit in adults with CF, complementary to administration of CFTR modulators.Study achieves clinically meaningful...

Read More

Laurent Pharmaceuticals Starts Phase 3 Study with Once-a-Day Oral COVID-19 Antiviral Treatment Candidate in Hospitalized Moderate-to-Severe Patients

15 February 2022

Following the positive outcome of a meeting with the FDA, a first patient was recruited in the Phase 3 expansion of...

Read More

EVENTS

Laurent Pharma to participate to BIO International Convention, June 5-8, 2023, Boston, MA

read more
Laurent Pharma to participate to BIO International Convention, June 13-16, 2022 – San Diego, CA
read more
Laurent Pharma to participate to BIO-Europe Spring, March 28-31, 2022
read more
Laurent Pharma to participate to BiotechGate, February 7-9, 2022
read more
Laurent Pharma to participate to Biotech Showcase, January 9-11 and 17-19, 2022
Laurent Pharma to participate to H.C. Wainwright 23rd Annual Global Investment Conference,
September 13-15, 2021
read more